UNC Lineberger News

Transplant survivors face chronic financial stressors

Transplant survivors face chronic financial stressors

Following a blood stem cell transplant, survivors can face serious economic challenges that may negatively affect their quality of life.

Transplant survivors face chronic financial stressors - Read More…

Dr. Lisa Carey authors editorial on neoadjuvant trials for breast cancer

Dr. Lisa Carey authors editorial on neoadjuvant trials for breast cancer

Lisa Carey, MD, authored an editorial, titled “Neoadjuvant Trials of Human Epidermal Growth Factor Receptor 2 Targeting: How Many Drugs Do We Need?”

Dr. Lisa Carey authors editorial on neoadjuvant trials for breast cancer - Read More…

Genetic pattern predicts response, metastasis in melanoma

Genetic pattern predicts response, metastasis in melanoma

A gene known to be mutated in many different cancers, but thought to be relatively unimportant in melanoma, may be a key indicator of how the disease will respond to radiation therapy and whether it will spread.

Genetic pattern predicts response, metastasis in melanoma - Read More…

Dibbert elected president of National Association of Cancer Center Development Officers

Dibbert elected president of National Association of Cancer Center Development Officers

Chapel Hill, NC – Debbie C. Dibbert, Director of External Affairs at UNC Lineberger Comprehensive Cancer Center, has been elected president of the National Association of Cancer Center Development Officers (NACCDO). She will serve a two-year term.

Dibbert elected president of National Association of Cancer Center Development Officers - Read More…

A Summer Final Four: Help Cornucopia House Win $25,000

A Summer Final Four: Help Cornucopia House Win $25,000

Votes, not baskets, will propel Cornucopia House to the Final Four in a national competition for a $25K mobile technology grant from AtlanticBT.

A Summer Final Four: Help Cornucopia House Win $25,000 - Read More…

Combination therapy for triple-negative breast cancer disappointing

Combination therapy for triple-negative breast cancer disappointing

CHAPEL HILL, N.C. – A recent clinical trial testing a combination therapy for basal-like (also known as triple-negative) breast cancer demonstrates that a combination of two drugs with promising preclinical results is not as effective as researchers had hoped.

Combination therapy for triple-negative breast cancer disappointing - Read More…